FY2027 EPS Estimates for IceCure Medical Cut by Analyst

IceCure Medical Ltd (NASDAQ:ICCM) – Stock analysts at Brookline Capital Management cut their FY2027 earnings per share (EPS) estimates for shares of IceCure Medical in a research report issued to clients and investors on Thursday, March 27th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn $0.22 per share for the year, down from their previous forecast of $0.23. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.32 EPS and FY2029 earnings at $0.42 EPS.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.07 million.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.50 price target on shares of IceCure Medical in a report on Friday.

IceCure Medical Stock Up 5.9 %

Shares of NASDAQ ICCM opened at $1.18 on Monday. The company has a market cap of $65.25 million, a price-to-earnings ratio of -4.05 and a beta of 0.37. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average is $1.31 and its 200 day moving average is $1.00. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC lifted its holdings in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned approximately 0.07% of IceCure Medical worth $44,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.